Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3, 313 patients. Issue 1 (13th December 2014)

• Record Type: Journal Article
• Authors: Maas, Monique; Nelemans, Patty J; Valentini, Vincenzo; Crane, Christopher H.; Capirci, Carlo; Rödel, Claus; Nash, Garrett M.; Kuo, Li‐Jen; Glynne‐Jones, Rob; García‐Aguilar, Julio; Suárez, Javier; Calvo, Felipe A.; Pucciarelli, Salvatore; Biondo, Sebastiano; Theodoropoulos, George; Lambregts, Doenja M.J.; Beets‐Tan, Regina G.H.; Beets, Geerard L.
• Is Part Of: International journal of cancer. Volume 137:Issue 1(2015:Jul. 01)
• Page Start: 212
• Page End: 220
• Publication Date: 2014-12-13
• Subjects: rectal cancer -- neoadjuvant treatment -- adjuvant chemotherapy -- survival -- response; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29355
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Recent literature suggests that the benefit of adjuvant chemotherapy (aCT) for rectal cancer patients might depend on the response to neoadjuvant chemoradiation (CRT). Aim was to evaluate whether the effect of aCT in rectal cancer is modified by response to CRT and to identify which patients benefit from aCT after CRT, by means of a pooled analysis of individual patient data from 13 datasets. Patients were categorized into three groups: pCR (ypT0N0), ypT1‐2 tumour and ypT3‐4 tumour. Hazard ratios (HR) for the effect of aCT were derived from multivariable Cox regression analyses. Primary outcome measure was recurrence‐free survival (RFS). One thousand seven hundred and twenty three (1723) (52%) of 3, 313 included patients received aCT. Eight hundred and ninety eight (898) patients had a pCR, 966 had a ypT1‐2 tumour and 1, 302 had a ypT3‐4 tumour. For 122 patients response, category was missing and 25 patients had ypT0N+. Median follow‐up for all patients was 51 (0–219) months. HR for RFS with 95% CI for patients treated with aCT were 1.25(0.68–2.29), 0.58(0.37–0.89) and 0.83(0.66–1.10) for patients with pCR, ypT1‐2 and ypT3‐4 tumours, respectively. The effect of aCT in rectal cancer patients treated with CRT differs between subgroups. Patients with a pCR after CRT may not benefit from aCT, whereas patients with residual tumour had superior outcomes when aCT was administered. The test for interaction did not reach statistical significance, but the results support further investigation of a more individualized approach to administer aCT after CRT and surgery based on pathologic staging. Abstract : What's new? Most patients with locally advanced rectal cancer receive adjuvant chemotherapy after neoadjuvant treatment and surgery. Based on a pooled analysis of individual patient data from 13 datasets, this study however shows that the benefit of adjuvant chemotherapy differs between subgroups, based on the response of patients to previous neoadjuvant chemoradiation. Patients with a complete response after chemoradiation may not benefit from adjuvant chemotherapy, whereas patients with residual tumour have superior outcomes when adjuvant chemotherapy was administered. The results support further investigation of a more individualized approach based on pathologic staging for the administration of adjuvant chemotherapy after chemoradiation and surgery.